Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial.

Usha Chakravarthy, Simon P. Harding, Chris A. Rogers, S.M. Downes, Andrew J. Lotery, Sarah Wordsworth, Barnaby R. Reeves

Research output: Contribution to journalArticlepeer-review

615 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial.'. Together they form a unique fingerprint.

Medicine & Life Sciences